Ablynx and Procter & Gamble extend Nanobody drug discovery development agreement to metabolic targets
Ablynx has announced that its drug discovery and development alliance with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company, has been extended to include metabolic disease targets. Through this agreement, Ablynx will use its unique and patent protected Nanobody(TM) platform to discover and develop drug candidates against targets specified by P&GP.
Under terms of the agreement, P&GP provides Ablynx with research and development funding, milestone payments, and royalties upon commercialization. Ablynx is responsible for discovering Nanobodies(TM) that meet an agreed product profile. P&GP assumes responsibility for the pre-clinical and clinical development of lead Nanobodies(TM), as well as the commercialization of any resulting drug products. The financial terms of the agreement are not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.